Contraception
Volume 73, Issue 4 , Pages 420-430, April 2006

Adequacy and safety of buccal misoprostol for cervical preparation prior to termination of second-trimester pregnancy

  • Ashlesha Patel

      Affiliations

    • Department of Obstetrics and Gynecology, John H. Stroger Jr. Hospital of Cook County, Chicago, IL 60612, USA
    • Medical Affairs Division, Planned Parenthood Federation of America, New York, NY 10001, USA
    • Corresponding Author InformationCorresponding author. Department of Obstetrics and Gynecology, 5th Floor, John H. Stroger Jr. Hospital, 1901 W Polk, Chicago, IL 60612, USA. Tel.: +1 312 740 3984; fax: +1 312 864 9269.
  • ,
  • Elizabeth Talmont

      Affiliations

    • Medical Affairs Division, Planned Parenthood Federation of America, New York, NY 10001, USA
  • ,
  • Johanna Morfesis

      Affiliations

    • Medical Affairs Division, Planned Parenthood Federation of America, New York, NY 10001, USA
  • ,
  • Murray Pelta

      Affiliations

    • Planned Parenthood Chicago Area, Chicago, IL 60603, USA
  • ,
  • Mary Gatter

      Affiliations

    • Planned Parenthood Los Angeles, Los Angeles, CA 90033, USA
  • ,
  • Michael R. Momtaz

      Affiliations

    • Planned Parenthood of New York City, New York, NY 10012, USA
  • ,
  • Harry Piotrowski

      Affiliations

    • Medical Affairs Division, Planned Parenthood Federation of America, New York, NY 10001, USA
  • ,
  • Vanessa Cullins

      Affiliations

    • Medical Affairs Division, Planned Parenthood Federation of America, New York, NY 10001, USA
  • ,
  • the Planned Parenthood Federation of America Buccal Misoprostol Waiver Group

      Affiliations

    • Planned Parenthood of New York City, New York, NY 10012, USA

Received 19 January 2005; received in revised form 13 September 2005; accepted 7 October 2005. published online 23 January 2006.

Abstract 

Objective

The objective of this retrospective, descriptive study is to assess the adequacy and safety of buccal misoprostol with and without laminaria for cervical preparation prior to second-trimester abortion.

Methods

We analyzed Planned Parenthood Federation of America data from 2218 elective dilation and evacuation (D&E) procedures conducted on women at 12 to 23 6/7 weeks of gestation from April 2002 to March 2003. Each woman received 400, 600 or 800 μg of buccal misoprostol with or without laminaria for preprocedural cervical preparation.

Results

Of the patients, 62% received 400 μg, 32% received 600 μg and 6% received 800 μg of buccal misoprostol; 42.8% had laminaria inserted for phased cervical preparation. The adequacy of cervical dilation was 88.7%. The D&E procedure was completed during a single surgical procedure for 99.8%. The overall adverse event rate was 19.39 per 1000 women, with a rate of 4.51 per 1000 women for serious adverse events.

Conclusions

This descriptive study suggests that use of buccal misoprostol with or without laminaria is effective and safe. If buccal misoprostol eliminates or reduces the need for phased, multiday laminaria 1–3 days prior to the surgical procedure, then its use may offer service advantages such as reduced number of clinic visits and fewer pelvic examinations per woman.

Keywords: Buccal misoprostol, Cervical preparation, Second-trimester termination, Abortion, Safety, Adequacy

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

PII: S0010-7824(05)00421-X

doi:10.1016/j.contraception.2005.10.004

Contraception
Volume 73, Issue 4 , Pages 420-430, April 2006